Cargando…
Is SARS-CoV-2 Neutralized More Effectively by IgM and IgA than IgG Having the Same Fab Region?
Recently, recombinant monoclonal antibodies (mAbs) of three Ig isotypes (IgG, IgA, and IgM) sharing the same anti-spike protein Fab region were developed; we evaluated their neutralizing abilities using a pseudo-typed lentivirus coated with the SARS-CoV-2 spike protein and ACE2-transfected Crandell–...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231813/ https://www.ncbi.nlm.nih.gov/pubmed/34199224 http://dx.doi.org/10.3390/pathogens10060751 |
_version_ | 1783713500274622464 |
---|---|
author | Pisil, Yalcin Yazici, Zafer Shida, Hisatoshi Miura, Tomoyuki |
author_facet | Pisil, Yalcin Yazici, Zafer Shida, Hisatoshi Miura, Tomoyuki |
author_sort | Pisil, Yalcin |
collection | PubMed |
description | Recently, recombinant monoclonal antibodies (mAbs) of three Ig isotypes (IgG, IgA, and IgM) sharing the same anti-spike protein Fab region were developed; we evaluated their neutralizing abilities using a pseudo-typed lentivirus coated with the SARS-CoV-2 spike protein and ACE2-transfected Crandell–Rees feline kidney cells as the host cell line. Although each of the anti-SARS-CoV-2 mAbs was able to neutralize the spike-coated lentiviruses, IgM and IgA neutralized the viral particles at 225-fold and 125-fold lower concentrations, respectively, than that of IgG. Our finding that the neutralization ability of Igs with the same Fab domain was dramatically higher for IgM and IgA than IgG mAbs suggests a strategy for developing effective and affordable antibody therapies for COVID-19. The efficient neutralization conferred by IgM and IgA mAbs can be explained by their capacity to bind multiple virions. While several IgG mAbs have been approved as therapeutics by the FDA, there are currently no IgM or IgA mAbs available. We suggest that mAbs with multiple antigen-binding sites such as IgM and IgA could be developed as the new generation of therapy. |
format | Online Article Text |
id | pubmed-8231813 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82318132021-06-26 Is SARS-CoV-2 Neutralized More Effectively by IgM and IgA than IgG Having the Same Fab Region? Pisil, Yalcin Yazici, Zafer Shida, Hisatoshi Miura, Tomoyuki Pathogens Hypothesis Recently, recombinant monoclonal antibodies (mAbs) of three Ig isotypes (IgG, IgA, and IgM) sharing the same anti-spike protein Fab region were developed; we evaluated their neutralizing abilities using a pseudo-typed lentivirus coated with the SARS-CoV-2 spike protein and ACE2-transfected Crandell–Rees feline kidney cells as the host cell line. Although each of the anti-SARS-CoV-2 mAbs was able to neutralize the spike-coated lentiviruses, IgM and IgA neutralized the viral particles at 225-fold and 125-fold lower concentrations, respectively, than that of IgG. Our finding that the neutralization ability of Igs with the same Fab domain was dramatically higher for IgM and IgA than IgG mAbs suggests a strategy for developing effective and affordable antibody therapies for COVID-19. The efficient neutralization conferred by IgM and IgA mAbs can be explained by their capacity to bind multiple virions. While several IgG mAbs have been approved as therapeutics by the FDA, there are currently no IgM or IgA mAbs available. We suggest that mAbs with multiple antigen-binding sites such as IgM and IgA could be developed as the new generation of therapy. MDPI 2021-06-13 /pmc/articles/PMC8231813/ /pubmed/34199224 http://dx.doi.org/10.3390/pathogens10060751 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Hypothesis Pisil, Yalcin Yazici, Zafer Shida, Hisatoshi Miura, Tomoyuki Is SARS-CoV-2 Neutralized More Effectively by IgM and IgA than IgG Having the Same Fab Region? |
title | Is SARS-CoV-2 Neutralized More Effectively by IgM and IgA than IgG Having the Same Fab Region? |
title_full | Is SARS-CoV-2 Neutralized More Effectively by IgM and IgA than IgG Having the Same Fab Region? |
title_fullStr | Is SARS-CoV-2 Neutralized More Effectively by IgM and IgA than IgG Having the Same Fab Region? |
title_full_unstemmed | Is SARS-CoV-2 Neutralized More Effectively by IgM and IgA than IgG Having the Same Fab Region? |
title_short | Is SARS-CoV-2 Neutralized More Effectively by IgM and IgA than IgG Having the Same Fab Region? |
title_sort | is sars-cov-2 neutralized more effectively by igm and iga than igg having the same fab region? |
topic | Hypothesis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231813/ https://www.ncbi.nlm.nih.gov/pubmed/34199224 http://dx.doi.org/10.3390/pathogens10060751 |
work_keys_str_mv | AT pisilyalcin issarscov2neutralizedmoreeffectivelybyigmandigathanigghavingthesamefabregion AT yazicizafer issarscov2neutralizedmoreeffectivelybyigmandigathanigghavingthesamefabregion AT shidahisatoshi issarscov2neutralizedmoreeffectivelybyigmandigathanigghavingthesamefabregion AT miuratomoyuki issarscov2neutralizedmoreeffectivelybyigmandigathanigghavingthesamefabregion |